tear_reaper personal page - To The Moon

tear_reaper

tear_reaper

No personal profile

11Follow

4Followers

1Topic

0Badge

2023-06-25

$EFUND LIQUOR(03189)$

2023-06-25

$EFUND LIQUOR(03189)$

2023-06-25

Give it 3 days for them to post a loss n go down in stock then after new financial year post record profits.. up $15 from today's price

2023-04-07

$Walt Disney(DIS)$ let's go get some shares!!

2023-08-30

$EFUND LIQUOR(03189)$

2023-04-09

Awesome as giveawy for Easter

2023-07-12

Wow

@TigerPicks:$ILPT Rise 25% Last Week: A High-Risk, High-Reward Opportunity?

2023-07-12

Great ariticle, would you like to share it?

@Chris23:Q3 2023 Outlook: Time for Cyclicals to Shine

2023-06-13

Great ariticle, would you like to share it?

@TigerEvents:Light up your investing with Tiger, play and win prizes worth up to USD 999

2023-06-03

Great ariticle, would you like to share it?

@DoTrading:SPX-Greedy...or Not...

2023-05-08

Great ariticle, would you like to share it?

Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting

2023-05-08

Great ariticle, would you like to share it?

Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting

2023-05-02

Great ariticle, would you like to share it?

@LMSunshine:🐂🐂🐂 About Apple🍎 Earnings & Share Price🥳

2023-05-02

Great ariticle, would you like to share it?

@TigerObserver:Weekly: Fed Decisions; Apple Earnings; FRC to highlight the Week

2023-05-02

Great ariticle, would you like to share it?

@Meme_Tiger:Top Meme Stocks| China Meme Mania is Back! Will FRC Go Bankrupt?

2023-04-25

$Lumen Technologies(LUMN)$

2023-04-20

$Tesla Motors(TSLA)$

2023-04-16

Great ariticle, would you like to share it?

@Tiger_comments:[TOPIC] Chip vs. New Energy: which one to choose?

2023-04-09

Great ariticle, would you like to share it?

Sorry, the original content has been removed

2023-04-09

Love this opportunity they have during easter

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4140236792428712","uuid":"4140236792428712","gmtCreate":1677135579698,"gmtModify":1677670404341,"name":"tear_reaper","pinyin":"tearreapertearreaper","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":11,"tweetSize":27,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":214373257248904,"gmtCreate":1693376936360,"gmtModify":1693376941487,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","text":"$EFUND LIQUOR(03189)$","images":[{"img":"https://community-static.tradeup.com/news/4e5281f41308c433a0fce5bca6823270","width":"720","height":"1175"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/214373257248904","isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":197144689627280,"gmtCreate":1689136186455,"gmtModify":1689136189551,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197144689627280","repostId":"196529503465720","repostType":1,"repost":{"id":196529503465720,"gmtCreate":1688990337219,"gmtModify":1688990355874,"author":{"id":"9000000000000572","authorId":"9000000000000572","name":"TigerPicks","avatar":"https://community-static.tradeup.com/news/a6d452b050ca40d986d2e3e339c5dab1","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000572","idStr":"9000000000000572"},"themes":[],"title":"$ILPT Rise 25% Last Week: A High-Risk, High-Reward Opportunity?","htmlText":"In today's edition, we will track the fundamental readings of long-term bullish companies in strong (TigerTrade Top 1 Gainer) concepts each week and look forward to your attention and discussion.Disclaimer:&nbsp;Capital at risk. This is not direct financial advice or a recommendation to acquire or dispose&nbsp;of any investment, but for communication only.It was a volatile week in the market. The best-performing concepts are security &amp; alarm services, industrial REITs and paper products.Considering the different perceptions of the stock, this time&nbsp;TigerPicks choose <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics Properties Trust(ILPT)$</a> to have a fundamental highlight to help users understand it better. <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics P</a>","listText":"In today's edition, we will track the fundamental readings of long-term bullish companies in strong (TigerTrade Top 1 Gainer) concepts each week and look forward to your attention and discussion.Disclaimer:&nbsp;Capital at risk. This is not direct financial advice or a recommendation to acquire or dispose&nbsp;of any investment, but for communication only.It was a volatile week in the market. The best-performing concepts are security &amp; alarm services, industrial REITs and paper products.Considering the different perceptions of the stock, this time&nbsp;TigerPicks choose <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics Properties Trust(ILPT)$</a> to have a fundamental highlight to help users understand it better. <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics P</a>","text":"In today's edition, we will track the fundamental readings of long-term bullish companies in strong (TigerTrade Top 1 Gainer) concepts each week and look forward to your attention and discussion.Disclaimer: Capital at risk. This is not direct financial advice or a recommendation to acquire or dispose of any investment, but for communication only.It was a volatile week in the market. The best-performing concepts are security & alarm services, industrial REITs and paper products.Considering the different perceptions of the stock, this time TigerPicks choose $Industrial Logistics Properties Trust(ILPT)$ to have a fundamental highlight to help users understand it better. $Industrial Logistics P","images":[{"img":"https://community-static.tradeup.com/news/16c98f85947521d1e543c680cccd6dd4","width":"422","height":"337"},{"img":"https://community-static.tradeup.com/news/62986eb54276bce4400be1e6ce6442cb","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/0349631409429b6107871196421a2e10","width":"1179","height":"336"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196529503465720","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197145405145240,"gmtCreate":1689136169445,"gmtModify":1689136172509,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197145405145240","repostId":"196493603737608","repostType":1,"repost":{"id":196493603737608,"gmtCreate":1688992714902,"gmtModify":1688996415096,"author":{"id":"3576190733155282","authorId":"3576190733155282","name":"Chris23","avatar":"https://community-static.tradeup.com/news/f76eb3b5f59a69dfc75dd237e6ba8d9c","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3576190733155282","idStr":"3576190733155282"},"themes":[],"title":"Q3 2023 Outlook: Time for Cyclicals to Shine","htmlText":"Following a stellar start to 2023, the S&amp;P 500 index has now recorded close to a 15% gain year-to-date. However, most of the rally has been concentrated in Large Cap US Tech stocks. The S&amp;P 500 Ex-Information Technology Index is up less than 2% YTD, heavily underperforming the S&amp;P. This underperformance can be attributed to the rise of Generative AI, with companies such as Nvidia, Meta and Tesla contributing to a significant portion of the gains in tech. Best-Performing Stocks of Q1 2023 | Morningstar Macroeconomic Update The US economy is showing no signs of recession despite echoes from the Fed maintaining its hawkish stance. The labour market remains extremely tight with the unemployment rate at 3.6% as of Jun 2023. Following this week’s mixed job data, traders will be looki","listText":"Following a stellar start to 2023, the S&amp;P 500 index has now recorded close to a 15% gain year-to-date. However, most of the rally has been concentrated in Large Cap US Tech stocks. The S&amp;P 500 Ex-Information Technology Index is up less than 2% YTD, heavily underperforming the S&amp;P. This underperformance can be attributed to the rise of Generative AI, with companies such as Nvidia, Meta and Tesla contributing to a significant portion of the gains in tech. Best-Performing Stocks of Q1 2023 | Morningstar Macroeconomic Update The US economy is showing no signs of recession despite echoes from the Fed maintaining its hawkish stance. The labour market remains extremely tight with the unemployment rate at 3.6% as of Jun 2023. Following this week’s mixed job data, traders will be looki","text":"Following a stellar start to 2023, the S&P 500 index has now recorded close to a 15% gain year-to-date. However, most of the rally has been concentrated in Large Cap US Tech stocks. The S&P 500 Ex-Information Technology Index is up less than 2% YTD, heavily underperforming the S&P. This underperformance can be attributed to the rise of Generative AI, with companies such as Nvidia, Meta and Tesla contributing to a significant portion of the gains in tech. Best-Performing Stocks of Q1 2023 | Morningstar Macroeconomic Update The US economy is showing no signs of recession despite echoes from the Fed maintaining its hawkish stance. The labour market remains extremely tight with the unemployment rate at 3.6% as of Jun 2023. Following this week’s mixed job data, traders will be looki","images":[{"img":"https://community-static.tradeup.com/news/419b91f9fb0ebfcd980bbccfb4dfb777","width":"822","height":"391"},{"img":"https://community-static.tradeup.com/news/e3120e60c1a6905174936d050d4a3b88","width":"660","height":"477"},{"img":"https://community-static.tradeup.com/news/b4d0b65639b058b64a984d0bd1d67ca0","width":"828","height":"415"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196493603737608","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191209908756760,"gmtCreate":1687700648406,"gmtModify":1687700652774,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Give it 3 days for them to post a loss n go down in stock then after new financial year post record profits.. up $15 from today's price","listText":"Give it 3 days for them to post a loss n go down in stock then after new financial year post record profits.. up $15 from today's price","text":"Give it 3 days for them to post a loss n go down in stock then after new financial year post record profits.. up $15 from today's price","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191209908756760","isVote":1,"tweetType":1,"viewCount":248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191209002357016,"gmtCreate":1687700427117,"gmtModify":1687700429760,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","text":"$EFUND LIQUOR(03189)$","images":[{"img":"https://community-static.tradeup.com/news/43693024da2238a953bef56fa58e8e15","width":"720","height":"1048"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191209002357016","isVote":1,"tweetType":1,"viewCount":479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":191208517423112,"gmtCreate":1687700281745,"gmtModify":1687700285968,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","text":"$EFUND LIQUOR(03189)$","images":[{"img":"https://community-static.tradeup.com/news/e94729e096c5821be9666d7eb2d6552d","width":"604","height":"939"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191208517423112","isVote":1,"tweetType":1,"viewCount":344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":186910590034000,"gmtCreate":1686671744098,"gmtModify":1686671747943,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186910590034000","repostId":"9970552160","repostType":1,"repost":{"id":9970552160,"gmtCreate":1684749190550,"gmtModify":1686053338540,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"Light up your investing with Tiger, play and win prizes worth up to USD 999","htmlText":"🔥 Join our exclusive \"Light up Your Investing\" campaign with Tiger! 💼💰Participate in our game and win fantastic USD 999 prizes! 🎉🤑Unveil the allure of various regions as you progress through exciting game levels. 🌍But wait, there's more! Along your journey, uncover hidden rewards and unlock exclusive bonuses that will supercharge your investing game! 🎁💎Not only will you gain valuable knowledge and insights, but you'll also compete with fellow investors for the top spot on our leaderboard! 🏆🚀Tag your friends and embark on this epic investing adventure together! Let's light up the world of investing with Tiger! 🐯✨Don't miss out on this limited-time opportunity! Campaign period: 6th June to 27th June.*T&amp;Cs apply.👉<a href=\"https://tigr.link/lightupau\" target=\"_blank\"> Click here to start p</a>","listText":"🔥 Join our exclusive \"Light up Your Investing\" campaign with Tiger! 💼💰Participate in our game and win fantastic USD 999 prizes! 🎉🤑Unveil the allure of various regions as you progress through exciting game levels. 🌍But wait, there's more! Along your journey, uncover hidden rewards and unlock exclusive bonuses that will supercharge your investing game! 🎁💎Not only will you gain valuable knowledge and insights, but you'll also compete with fellow investors for the top spot on our leaderboard! 🏆🚀Tag your friends and embark on this epic investing adventure together! Let's light up the world of investing with Tiger! 🐯✨Don't miss out on this limited-time opportunity! Campaign period: 6th June to 27th June.*T&amp;Cs apply.👉<a href=\"https://tigr.link/lightupau\" target=\"_blank\"> Click here to start p</a>","text":"🔥 Join our exclusive \"Light up Your Investing\" campaign with Tiger! 💼💰Participate in our game and win fantastic USD 999 prizes! 🎉🤑Unveil the allure of various regions as you progress through exciting game levels. 🌍But wait, there's more! Along your journey, uncover hidden rewards and unlock exclusive bonuses that will supercharge your investing game! 🎁💎Not only will you gain valuable knowledge and insights, but you'll also compete with fellow investors for the top spot on our leaderboard! 🏆🚀Tag your friends and embark on this epic investing adventure together! Let's light up the world of investing with Tiger! 🐯✨Don't miss out on this limited-time opportunity! Campaign period: 6th June to 27th June.*T&Cs apply.👉 Click here to start p","images":[{"img":"https://community-static.tradeup.com/news/93315f0145d9ad782d2cab5f5dea10d7","width":"1200","height":"675"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9970552160","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":1,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183342836047952,"gmtCreate":1685782737468,"gmtModify":1685782741263,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183342836047952","repostId":"183318861013008","repostType":1,"repost":{"id":183318861013008,"gmtCreate":1685777195696,"gmtModify":1685778488930,"author":{"id":"4112162097902942","authorId":"4112162097902942","name":"DoTrading","avatar":"https://community-static.tradeup.com/news/b836687d88c2c5ee60f65e3d53461ef7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4112162097902942","idStr":"4112162097902942"},"themes":[],"title":"SPX-Greedy...or Not...","htmlText":"CONTENT: Summary - Main events - Market scenario - SPX levels - Agenda. <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> rose 1.5%, taking its weekly gain to 1.8%. <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> continued its advance with 1.1% to hit a 52-week high. He gained 2% weekly, extending his winning streak to six weeks. (longest winning streak since January 2020). <a href=\"https://ttm.financial/S/.DJI\">$DJIA(.DJI)$</a> by 2.1%, with the biggest one-day point gain for the Dow Jones since Nov. 30, 2022 (about 701 points). Although big tech stocks have gone it alone in recent weeks, raising questions about the real breadth of the market, on Friday all 11 sectors of the S&amp;P 500 rose... Market valuation The reset in VVIX and skew this week has been absol","listText":"CONTENT: Summary - Main events - Market scenario - SPX levels - Agenda. <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> rose 1.5%, taking its weekly gain to 1.8%. <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> continued its advance with 1.1% to hit a 52-week high. He gained 2% weekly, extending his winning streak to six weeks. (longest winning streak since January 2020). <a href=\"https://ttm.financial/S/.DJI\">$DJIA(.DJI)$</a> by 2.1%, with the biggest one-day point gain for the Dow Jones since Nov. 30, 2022 (about 701 points). Although big tech stocks have gone it alone in recent weeks, raising questions about the real breadth of the market, on Friday all 11 sectors of the S&amp;P 500 rose... Market valuation The reset in VVIX and skew this week has been absol","text":"CONTENT: Summary - Main events - Market scenario - SPX levels - Agenda. $S&P 500(.SPX)$ rose 1.5%, taking its weekly gain to 1.8%. $NASDAQ(.IXIC)$ continued its advance with 1.1% to hit a 52-week high. He gained 2% weekly, extending his winning streak to six weeks. (longest winning streak since January 2020). $DJIA(.DJI)$ by 2.1%, with the biggest one-day point gain for the Dow Jones since Nov. 30, 2022 (about 701 points). Although big tech stocks have gone it alone in recent weeks, raising questions about the real breadth of the market, on Friday all 11 sectors of the S&P 500 rose... Market valuation The reset in VVIX and skew this week has been absol","images":[{"img":"https://community-static.tradeup.com/news/96177d81fd16df6c76a10c71a34ad39e","width":"613","height":"401"},{"img":"https://community-static.tradeup.com/news/634724ae91624bc074c808c6629bbc0c","width":"801","height":"516"},{"img":"https://community-static.tradeup.com/news/7c99c2fe88b48164f47acb826811b43c","width":"1167","height":"971"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183318861013008","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947482530,"gmtCreate":1683503517221,"gmtModify":1683503519944,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947482530","repostId":"2332241389","repostType":2,"repost":{"id":"2332241389","pubTimestamp":1683113400,"share":"https://ttm.financial/m/news/2332241389?lang=&edition=fundamental","pubTime":"2023-05-03 19:30","market":"us","language":"en","title":"Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2332241389","media":"GlobeNewswire","summary":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomi","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/99cgRTjjmIlIU2OVWMbZ5w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/53a1e9b470d0b8db47e46ddd9872cbf3\" title=\"HMI Logo_020216.jpg\" vspace=\"5\"/>\n<p><strong><em>-</em></strong> <strong><em>First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -</em></strong><br/></p>\n<p>BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene &amp; Cell Therapy (ASGCT) 26<sup>th </sup>Annual Meeting from May 16-20, 2023.</p>\n<p>“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”<br/><br/>Homology’s ASGCT 2023 presentations will include:<br/><br/></p>\n<p><strong>HMI-104: GTx-mAb Development Candidate for PNH</strong><br/>Preclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 386</li>\n</ul>\n<p><strong>AAVHSC Platform</strong><br/>Ocular Biodistribution of AAVHSCs Across Species and Routes of Administration<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 376</li>\n</ul>\n<p><strong>Immunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS II</strong><br/>Targeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches<br/></p>\n<ul type=\"disc\">\n<li>Thursday, May 18 at 12:00 p.m. PT</li>\n<li>Abstract # 989<br/></li>\n</ul>\n<p><strong>HMI-204: Gene Therapy Candidate for MLD</strong><br/>Gene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1312</li>\n</ul>\n<p><strong>AAVHSC Re-Dosing</strong><br/>Re-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1355</li>\n</ul>\n<p><strong>AAVHSC-Mediated, Homologous Recombination-Based Gene Editing</strong><br/>Method for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1497<br/></li>\n</ul>\n<p>The abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.</p>\n<p><strong>About Homology Medicines, Inc.</strong><br/>Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines <em>in vivo</em> through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.<br/></p>\n<p><strong>Forward-Looking Statements </strong><br/>This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.<br/></p>\n<p><strong>Company Contacts:</strong><br/>Cara Mayfield<br/>Vice President, Patient Advocacy<br/>and Corporate Communications<br/>cmayfield@homologymedicines.com<br/>781-691-3510<br/><br/><strong>Investor Contact:</strong><br/>Brad Smith <br/>Chief Financial and Business Officer <br/>bsmith@homologymedicines.com <br/>781-301-7277<br/><br/><br/><br/><br/><br/><br/><br/><br/><br/><br/></p>\n<br/>\n<img src=\"https://ml.globenewswire.com/media/ZTI0NzJlY2MtMGM1Yy00ZjY5LWI2OGEtZTE5MDE4YzdmZjZlLTExMDk1MTQ=/tiny/Homology-Medicines-Inc-.png\"/>\n<br/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHomology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-03 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE ...</p>\n\n<a href=\"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/PnhYAqM5zRCGitBIclIvxg--~B/aD05NTA7dz0zODgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/35ccf701601c31a2229a441cf35a80c2","relate_stocks":{"NGD":"New Gold","MDCO":"麦迪逊医药","BK4139":"生物科技","GENE":"基因技术ADR","BK4570":"地缘局势概念股","BK4017":"黄金","BK4121":"生命科学工具和服务","BK4535":"淡马锡持仓"},"source_url":"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2332241389","content_text":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting from May 16-20, 2023.\n“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”Homology’s ASGCT 2023 presentations will include:\nHMI-104: GTx-mAb Development Candidate for PNHPreclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 386\n\nAAVHSC PlatformOcular Biodistribution of AAVHSCs Across Species and Routes of Administration\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 376\n\nImmunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS IITargeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches\n\nThursday, May 18 at 12:00 p.m. PT\nAbstract # 989\n\nHMI-204: Gene Therapy Candidate for MLDGene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1312\n\nAAVHSC Re-DosingRe-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1355\n\nAAVHSC-Mediated, Homologous Recombination-Based Gene EditingMethod for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1497\n\nThe abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.\nAbout Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.\nForward-Looking Statements This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.\nCompany Contacts:Cara MayfieldVice President, Patient Advocacyand Corporate Communicationscmayfield@homologymedicines.com781-691-3510Investor Contact:Brad Smith Chief Financial and Business Officer bsmith@homologymedicines.com 781-301-7277","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947482295,"gmtCreate":1683503510618,"gmtModify":1683503514291,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947482295","repostId":"2332241389","repostType":2,"repost":{"id":"2332241389","pubTimestamp":1683113400,"share":"https://ttm.financial/m/news/2332241389?lang=&edition=fundamental","pubTime":"2023-05-03 19:30","market":"us","language":"en","title":"Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2332241389","media":"GlobeNewswire","summary":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomi","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/99cgRTjjmIlIU2OVWMbZ5w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/53a1e9b470d0b8db47e46ddd9872cbf3\" title=\"HMI Logo_020216.jpg\" vspace=\"5\"/>\n<p><strong><em>-</em></strong> <strong><em>First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -</em></strong><br/></p>\n<p>BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene &amp; Cell Therapy (ASGCT) 26<sup>th </sup>Annual Meeting from May 16-20, 2023.</p>\n<p>“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”<br/><br/>Homology’s ASGCT 2023 presentations will include:<br/><br/></p>\n<p><strong>HMI-104: GTx-mAb Development Candidate for PNH</strong><br/>Preclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 386</li>\n</ul>\n<p><strong>AAVHSC Platform</strong><br/>Ocular Biodistribution of AAVHSCs Across Species and Routes of Administration<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 376</li>\n</ul>\n<p><strong>Immunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS II</strong><br/>Targeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches<br/></p>\n<ul type=\"disc\">\n<li>Thursday, May 18 at 12:00 p.m. PT</li>\n<li>Abstract # 989<br/></li>\n</ul>\n<p><strong>HMI-204: Gene Therapy Candidate for MLD</strong><br/>Gene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1312</li>\n</ul>\n<p><strong>AAVHSC Re-Dosing</strong><br/>Re-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1355</li>\n</ul>\n<p><strong>AAVHSC-Mediated, Homologous Recombination-Based Gene Editing</strong><br/>Method for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1497<br/></li>\n</ul>\n<p>The abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.</p>\n<p><strong>About Homology Medicines, Inc.</strong><br/>Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines <em>in vivo</em> through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.<br/></p>\n<p><strong>Forward-Looking Statements </strong><br/>This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.<br/></p>\n<p><strong>Company Contacts:</strong><br/>Cara Mayfield<br/>Vice President, Patient Advocacy<br/>and Corporate Communications<br/>cmayfield@homologymedicines.com<br/>781-691-3510<br/><br/><strong>Investor Contact:</strong><br/>Brad Smith <br/>Chief Financial and Business Officer <br/>bsmith@homologymedicines.com <br/>781-301-7277<br/><br/><br/><br/><br/><br/><br/><br/><br/><br/><br/></p>\n<br/>\n<img src=\"https://ml.globenewswire.com/media/ZTI0NzJlY2MtMGM1Yy00ZjY5LWI2OGEtZTE5MDE4YzdmZjZlLTExMDk1MTQ=/tiny/Homology-Medicines-Inc-.png\"/>\n<br/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHomology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-03 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE ...</p>\n\n<a href=\"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/PnhYAqM5zRCGitBIclIvxg--~B/aD05NTA7dz0zODgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/35ccf701601c31a2229a441cf35a80c2","relate_stocks":{"NGD":"New Gold","MDCO":"麦迪逊医药","BK4139":"生物科技","GENE":"基因技术ADR","BK4570":"地缘局势概念股","BK4017":"黄金","BK4121":"生命科学工具和服务","BK4535":"淡马锡持仓"},"source_url":"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2332241389","content_text":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting from May 16-20, 2023.\n“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”Homology’s ASGCT 2023 presentations will include:\nHMI-104: GTx-mAb Development Candidate for PNHPreclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 386\n\nAAVHSC PlatformOcular Biodistribution of AAVHSCs Across Species and Routes of Administration\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 376\n\nImmunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS IITargeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches\n\nThursday, May 18 at 12:00 p.m. PT\nAbstract # 989\n\nHMI-204: Gene Therapy Candidate for MLDGene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1312\n\nAAVHSC Re-DosingRe-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1355\n\nAAVHSC-Mediated, Homologous Recombination-Based Gene EditingMethod for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1497\n\nThe abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.\nAbout Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.\nForward-Looking Statements This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.\nCompany Contacts:Cara MayfieldVice President, Patient Advocacyand Corporate Communicationscmayfield@homologymedicines.com781-691-3510Investor Contact:Brad Smith Chief Financial and Business Officer bsmith@homologymedicines.com 781-301-7277","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947870321,"gmtCreate":1682989638663,"gmtModify":1682989642276,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947870321","repostId":"9947813329","repostType":1,"repost":{"id":9947813329,"gmtCreate":1682870524062,"gmtModify":1682901733820,"author":{"id":"4113904591642392","authorId":"4113904591642392","name":"LMSunshine","avatar":"https://community-static.tradeup.com/news/0ad636f2490d8428fcee9da6d669e46c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4113904591642392","idStr":"4113904591642392"},"themes":[],"title":"🐂🐂🐂 About Apple🍎 Earnings & Share Price🥳","htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;ended at an 8-month peak of $169.68 on 28/4 (Fri), the highest level since 26/8/22🐂🐂🐂 At its current valuation, 🍎 has a market cap of $2.68 trillion, making it the most valuable company trading on the 🇺🇸 stock exchange. Shares are up 30.6% so far in 2023, almost quadrupling the 7.7% rise in the S&amp;P 500 index, was&nbsp;outperforming the broader market by a wide margin over the same timeframe🥳🥳🥳 ⭐️&nbsp;I expect 🍎 to follow 🐂-ish earnings reports MSFT, GOOGL, META,&nbsp;&amp; AMZN last week&nbsp;<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/META\">$Meta Platforms</a>","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;ended at an 8-month peak of $169.68 on 28/4 (Fri), the highest level since 26/8/22🐂🐂🐂 At its current valuation, 🍎 has a market cap of $2.68 trillion, making it the most valuable company trading on the 🇺🇸 stock exchange. Shares are up 30.6% so far in 2023, almost quadrupling the 7.7% rise in the S&amp;P 500 index, was&nbsp;outperforming the broader market by a wide margin over the same timeframe🥳🥳🥳 ⭐️&nbsp;I expect 🍎 to follow 🐂-ish earnings reports MSFT, GOOGL, META,&nbsp;&amp; AMZN last week&nbsp;<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/META\">$Meta Platforms</a>","text":"$Apple(AAPL)$ ended at an 8-month peak of $169.68 on 28/4 (Fri), the highest level since 26/8/22🐂🐂🐂 At its current valuation, 🍎 has a market cap of $2.68 trillion, making it the most valuable company trading on the 🇺🇸 stock exchange. Shares are up 30.6% so far in 2023, almost quadrupling the 7.7% rise in the S&P 500 index, was outperforming the broader market by a wide margin over the same timeframe🥳🥳🥳 ⭐️ I expect 🍎 to follow 🐂-ish earnings reports MSFT, GOOGL, META, & AMZN last week $Alphabet(GOOGL)$ Bullish$Amazon.com(AMZN)$ Bullish$Meta Platforms","images":[{"img":"https://community-static.tradeup.com/news/780d5c3ae21556b4cda00fddb1bb9b1c","width":"873","height":"808"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947813329","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947870950,"gmtCreate":1682989623170,"gmtModify":1682989627004,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947870950","repostId":"9947884997","repostType":1,"repost":{"id":9947884997,"gmtCreate":1682922581919,"gmtModify":1682923112776,"author":{"id":"9000000000000439","authorId":"9000000000000439","name":"TigerObserver","avatar":"https://static.tigerbbs.com/2f3a05d038882153678ee817929431fc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000439","idStr":"9000000000000439"},"themes":[],"title":"Weekly: Fed Decisions; Apple Earnings; FRC to highlight the Week","htmlText":"US MARKET RECAPLast week, all the major index close in green with a deep V-shaped pattern. The blue-chip index, Dow added 0.86%, while the S&amp;P 500 rose 0.87%. The Nasdaq advanced 1.28% as Big Tech earnings took center stage.For April, the Dow gained 2.48% to notch its best monthly stretch since January, while the benchmark index gained 1.46%. The tech-heavy index posted marginal gains.Earnings reports from major tech companies dominated much of last week’s market debate, fueling the narrative that earnings are faring better-than-feared, despite many widespread macroeconomic concerns.So far, a little over half of S&amp;P 500 companies have reported earnings, with more than 79% and about 72% surpassing earnings and sales expectations, respectively. First-quarter earnings are currently on","listText":"US MARKET RECAPLast week, all the major index close in green with a deep V-shaped pattern. The blue-chip index, Dow added 0.86%, while the S&amp;P 500 rose 0.87%. The Nasdaq advanced 1.28% as Big Tech earnings took center stage.For April, the Dow gained 2.48% to notch its best monthly stretch since January, while the benchmark index gained 1.46%. The tech-heavy index posted marginal gains.Earnings reports from major tech companies dominated much of last week’s market debate, fueling the narrative that earnings are faring better-than-feared, despite many widespread macroeconomic concerns.So far, a little over half of S&amp;P 500 companies have reported earnings, with more than 79% and about 72% surpassing earnings and sales expectations, respectively. First-quarter earnings are currently on","text":"US MARKET RECAPLast week, all the major index close in green with a deep V-shaped pattern. The blue-chip index, Dow added 0.86%, while the S&P 500 rose 0.87%. The Nasdaq advanced 1.28% as Big Tech earnings took center stage.For April, the Dow gained 2.48% to notch its best monthly stretch since January, while the benchmark index gained 1.46%. The tech-heavy index posted marginal gains.Earnings reports from major tech companies dominated much of last week’s market debate, fueling the narrative that earnings are faring better-than-feared, despite many widespread macroeconomic concerns.So far, a little over half of S&P 500 companies have reported earnings, with more than 79% and about 72% surpassing earnings and sales expectations, respectively. First-quarter earnings are currently on","images":[{"img":"https://community-static.tradeup.com/news/bf50b77b83d4fe0ebd4152acd2c424e5","width":"974","height":"1110"},{"img":"https://community-static.tradeup.com/news/d6a9ce360893b3b14136d9dc3804bf07","width":"1290","height":"498"},{"img":"https://community-static.tradeup.com/news/334f7f736dd80a6544ee9931d422b2ff","width":"1080","height":"1920"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947884997","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947870042,"gmtCreate":1682989558987,"gmtModify":1682989562428,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947870042","repostId":"9947897984","repostType":1,"repost":{"id":9947897984,"gmtCreate":1682822470348,"gmtModify":1682822503705,"author":{"id":"10000000000010945","authorId":"10000000000010945","name":"Meme_Tiger","avatar":"https://community-static.tradeup.com/news/eb1a09788252e1f02cd561cbf0b1ac99","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"10000000000010945","idStr":"10000000000010945"},"themes":[],"title":"Top Meme Stocks| China Meme Mania is Back! Will FRC Go Bankrupt?","htmlText":"Hi, tigers! I gonna track meme stocks’ movement every week and inform you of the hottest meme stocks in one week and why did they gain most attention. If you were also interested in meme stocks, follow me and learn the news about short squeeze every Friday! 💖💖I gonna present you the top gainers/losers in meme stocks this week!Market manipulation behind China meme stocks mania?Nate Anderson, the Founder of short seller activist firm Hindenburg Research, believes that market manipulation is the culprit behind the outsized gains&nbsp;of <a href=\"https://ttm.financial/S/TOP\">$Zhong Yang Financial Group Ltd(TOP)$</a>, <a href=\"https://ttm.financial/S/MEGL\">$Magic Empire Global Ltd(MEGL)$</a> and <a href=\"https://ttm.financial/S/HKD\">$AMTD Digital Inc.(HKD)$</a> .Since last November, Anderson ha","listText":"Hi, tigers! I gonna track meme stocks’ movement every week and inform you of the hottest meme stocks in one week and why did they gain most attention. If you were also interested in meme stocks, follow me and learn the news about short squeeze every Friday! 💖💖I gonna present you the top gainers/losers in meme stocks this week!Market manipulation behind China meme stocks mania?Nate Anderson, the Founder of short seller activist firm Hindenburg Research, believes that market manipulation is the culprit behind the outsized gains&nbsp;of <a href=\"https://ttm.financial/S/TOP\">$Zhong Yang Financial Group Ltd(TOP)$</a>, <a href=\"https://ttm.financial/S/MEGL\">$Magic Empire Global Ltd(MEGL)$</a> and <a href=\"https://ttm.financial/S/HKD\">$AMTD Digital Inc.(HKD)$</a> .Since last November, Anderson ha","text":"Hi, tigers! I gonna track meme stocks’ movement every week and inform you of the hottest meme stocks in one week and why did they gain most attention. If you were also interested in meme stocks, follow me and learn the news about short squeeze every Friday! 💖💖I gonna present you the top gainers/losers in meme stocks this week!Market manipulation behind China meme stocks mania?Nate Anderson, the Founder of short seller activist firm Hindenburg Research, believes that market manipulation is the culprit behind the outsized gains of $Zhong Yang Financial Group Ltd(TOP)$, $Magic Empire Global Ltd(MEGL)$ and $AMTD Digital Inc.(HKD)$ .Since last November, Anderson ha","images":[{"img":"https://community-static.tradeup.com/news/ed8bf5f917994ecf93bc0a19ff6630a8","width":"1587","height":"2245"},{"img":"https://community-static.tradeup.com/news/c13649877e01553d6c61d48db7e5a002","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/53438bceca949c0b15f9236457167634","width":"560","height":"240"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947897984","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":6,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947908126,"gmtCreate":1682417828766,"gmtModify":1682417832063,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/LUMN\">$Lumen Technologies(LUMN)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/LUMN\">$Lumen Technologies(LUMN)$ &nbsp;</a>","text":"$Lumen Technologies(LUMN)$","images":[{"img":"https://community-static.tradeup.com/news/457f0f1e3fd88eb3fd110aa06d6af1ff","width":"720","height":"1234"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947908126","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9944406031,"gmtCreate":1681982854323,"gmtModify":1681982858247,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ &nbsp;</a>","text":"$Tesla Motors(TSLA)$","images":[{"img":"https://community-static.tradeup.com/news/06caafdcb35963c0104fa529a0c34fc3","width":"720","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9944406031","isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9945769302,"gmtCreate":1681599157107,"gmtModify":1681599161012,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945769302","repostId":"9945610651","repostType":1,"repost":{"id":9945610651,"gmtCreate":1681446196173,"gmtModify":1681446338358,"author":{"id":"3501196737273098","authorId":"3501196737273098","name":"Tiger_comments","avatar":"https://community-static.tradeup.com/news/227887b200e9925968650d5db4a8bfb3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3501196737273098","idStr":"3501196737273098"},"themes":[],"title":"[TOPIC] Chip vs. New Energy: which one to choose?","htmlText":"The market’s favorite has been changing over years as ChatGPT concept is the most-heated topic. While back in 2021, new energy vehicle was the beloved one.New King - SemiconductorSince the end of last year, ChatGPT concept has become very popular. The AI sector has also risen accordingly. The ChatGPT concept in the US stock market has risen by 30%.Since this year is a technology bull market, the chip behind artificial intelligence will naturally not be absent. On April 6, the ChatGPT official announced the suspension of the Plus version (a $20/month subscription version).The reason is due to the tightness of the computing power and the increased demand for high-end chips. With the development of the AI, the demand for high-performance GPUs will also increase.In addition, the market general","listText":"The market’s favorite has been changing over years as ChatGPT concept is the most-heated topic. While back in 2021, new energy vehicle was the beloved one.New King - SemiconductorSince the end of last year, ChatGPT concept has become very popular. The AI sector has also risen accordingly. The ChatGPT concept in the US stock market has risen by 30%.Since this year is a technology bull market, the chip behind artificial intelligence will naturally not be absent. On April 6, the ChatGPT official announced the suspension of the Plus version (a $20/month subscription version).The reason is due to the tightness of the computing power and the increased demand for high-end chips. With the development of the AI, the demand for high-performance GPUs will also increase.In addition, the market general","text":"The market’s favorite has been changing over years as ChatGPT concept is the most-heated topic. While back in 2021, new energy vehicle was the beloved one.New King - SemiconductorSince the end of last year, ChatGPT concept has become very popular. The AI sector has also risen accordingly. The ChatGPT concept in the US stock market has risen by 30%.Since this year is a technology bull market, the chip behind artificial intelligence will naturally not be absent. On April 6, the ChatGPT official announced the suspension of the Plus version (a $20/month subscription version).The reason is due to the tightness of the computing power and the increased demand for high-end chips. With the development of the AI, the demand for high-performance GPUs will also increase.In addition, the market general","images":[{"img":"https://community-static.tradeup.com/news/53eefa35ac2faa2727117903497aec91","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/d5e6e9ebaea7764a2f57b3666f7b054e","width":"837","height":"371"},{"img":"https://community-static.tradeup.com/news/5ffbc693d8e02a960f8113d15348ab7e","width":"1245","height":"320"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945610651","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9946706759,"gmtCreate":1681046667372,"gmtModify":1681046670889,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Awesome as giveawy for Easter&nbsp;","listText":"Awesome as giveawy for Easter&nbsp;","text":"Awesome as giveawy for Easter","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946706759","isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9946706528,"gmtCreate":1681046652465,"gmtModify":1681046655830,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946706528","repostId":"9946706174","repostType":1,"isVote":1,"tweetType":1,"viewCount":61,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9946706649,"gmtCreate":1681046628581,"gmtModify":1681046635231,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Love this opportunity they have during easter","listText":"Love this opportunity they have during easter","text":"Love this opportunity they have during easter","images":[{"img":"https://community-static.tradeup.com/news/1d94e85eaebdbfcb6ef32b9b6aed7eb3","width":"580","height":"2319"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946706649","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9946902717,"gmtCreate":1680830031239,"gmtModify":1680830033053,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4140236792428712","idStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946902717","repostId":"9946903736","repostType":1,"repost":{"id":9946903736,"gmtCreate":1680829445726,"gmtModify":1680829449768,"author":{"id":"3551587705354640","authorId":"3551587705354640","name":"niqqqy","avatar":"https://static.tigerbbs.com/4affdd240894d23464fa6ad6729eed78","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3551587705354640","idStr":"3551587705354640"},"themes":[],"htmlText":"👍👍👍👍👍👍","listText":"👍👍👍👍👍👍","text":"👍👍👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946903736","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":191209002357016,"gmtCreate":1687700427117,"gmtModify":1687700429760,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","text":"$EFUND LIQUOR(03189)$","images":[{"img":"https://community-static.tradeup.com/news/43693024da2238a953bef56fa58e8e15","width":"720","height":"1048"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191209002357016","isVote":1,"tweetType":1,"viewCount":479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":191208517423112,"gmtCreate":1687700281745,"gmtModify":1687700285968,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","text":"$EFUND LIQUOR(03189)$","images":[{"img":"https://community-static.tradeup.com/news/e94729e096c5821be9666d7eb2d6552d","width":"604","height":"939"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191208517423112","isVote":1,"tweetType":1,"viewCount":344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":191209908756760,"gmtCreate":1687700648406,"gmtModify":1687700652774,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Give it 3 days for them to post a loss n go down in stock then after new financial year post record profits.. up $15 from today's price","listText":"Give it 3 days for them to post a loss n go down in stock then after new financial year post record profits.. up $15 from today's price","text":"Give it 3 days for them to post a loss n go down in stock then after new financial year post record profits.. up $15 from today's price","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191209908756760","isVote":1,"tweetType":1,"viewCount":248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9946902505,"gmtCreate":1680830015308,"gmtModify":1680830018027,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIS\">$Walt Disney(DIS)$&nbsp;</a> let's go get some shares!!","listText":"<a href=\"https://ttm.financial/S/DIS\">$Walt Disney(DIS)$&nbsp;</a> let's go get some shares!!","text":"$Walt Disney(DIS)$ let's go get some shares!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9946902505","isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4109495603404680","authorId":"4109495603404680","name":"Tdawg86","avatar":"https://community-static.tradeup.com/news/a26d1380dfbd4b33537d8d4b8a10b87d","crmLevel":1,"crmLevelSwitch":0,"idStr":"4109495603404680","authorIdStr":"4109495603404680"},"content":"Works out about $100 USD","text":"Works out about $100 USD","html":"Works out about $100 USD"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":214373257248904,"gmtCreate":1693376936360,"gmtModify":1693376941487,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/03189\">$EFUND LIQUOR(03189)$ &nbsp;</a>","text":"$EFUND LIQUOR(03189)$","images":[{"img":"https://community-static.tradeup.com/news/4e5281f41308c433a0fce5bca6823270","width":"720","height":"1175"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/214373257248904","isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9946706759,"gmtCreate":1681046667372,"gmtModify":1681046670889,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Awesome as giveawy for Easter&nbsp;","listText":"Awesome as giveawy for Easter&nbsp;","text":"Awesome as giveawy for Easter","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946706759","isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197144689627280,"gmtCreate":1689136186455,"gmtModify":1689136189551,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197144689627280","repostId":"196529503465720","repostType":1,"repost":{"id":196529503465720,"gmtCreate":1688990337219,"gmtModify":1688990355874,"author":{"id":"9000000000000572","authorId":"9000000000000572","name":"TigerPicks","avatar":"https://community-static.tradeup.com/news/a6d452b050ca40d986d2e3e339c5dab1","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000572","authorIdStr":"9000000000000572"},"themes":[],"title":"$ILPT Rise 25% Last Week: A High-Risk, High-Reward Opportunity?","htmlText":"In today's edition, we will track the fundamental readings of long-term bullish companies in strong (TigerTrade Top 1 Gainer) concepts each week and look forward to your attention and discussion.Disclaimer:&nbsp;Capital at risk. This is not direct financial advice or a recommendation to acquire or dispose&nbsp;of any investment, but for communication only.It was a volatile week in the market. The best-performing concepts are security &amp; alarm services, industrial REITs and paper products.Considering the different perceptions of the stock, this time&nbsp;TigerPicks choose <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics Properties Trust(ILPT)$</a> to have a fundamental highlight to help users understand it better. <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics P</a>","listText":"In today's edition, we will track the fundamental readings of long-term bullish companies in strong (TigerTrade Top 1 Gainer) concepts each week and look forward to your attention and discussion.Disclaimer:&nbsp;Capital at risk. This is not direct financial advice or a recommendation to acquire or dispose&nbsp;of any investment, but for communication only.It was a volatile week in the market. The best-performing concepts are security &amp; alarm services, industrial REITs and paper products.Considering the different perceptions of the stock, this time&nbsp;TigerPicks choose <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics Properties Trust(ILPT)$</a> to have a fundamental highlight to help users understand it better. <a href=\"https://ttm.financial/S/ILPT\">$Industrial Logistics P</a>","text":"In today's edition, we will track the fundamental readings of long-term bullish companies in strong (TigerTrade Top 1 Gainer) concepts each week and look forward to your attention and discussion.Disclaimer: Capital at risk. This is not direct financial advice or a recommendation to acquire or dispose of any investment, but for communication only.It was a volatile week in the market. The best-performing concepts are security & alarm services, industrial REITs and paper products.Considering the different perceptions of the stock, this time TigerPicks choose $Industrial Logistics Properties Trust(ILPT)$ to have a fundamental highlight to help users understand it better. $Industrial Logistics P","images":[{"img":"https://community-static.tradeup.com/news/16c98f85947521d1e543c680cccd6dd4","width":"422","height":"337"},{"img":"https://community-static.tradeup.com/news/62986eb54276bce4400be1e6ce6442cb","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/0349631409429b6107871196421a2e10","width":"1179","height":"336"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196529503465720","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197145405145240,"gmtCreate":1689136169445,"gmtModify":1689136172509,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197145405145240","repostId":"196493603737608","repostType":1,"repost":{"id":196493603737608,"gmtCreate":1688992714902,"gmtModify":1688996415096,"author":{"id":"3576190733155282","authorId":"3576190733155282","name":"Chris23","avatar":"https://community-static.tradeup.com/news/f76eb3b5f59a69dfc75dd237e6ba8d9c","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3576190733155282","authorIdStr":"3576190733155282"},"themes":[],"title":"Q3 2023 Outlook: Time for Cyclicals to Shine","htmlText":"Following a stellar start to 2023, the S&amp;P 500 index has now recorded close to a 15% gain year-to-date. However, most of the rally has been concentrated in Large Cap US Tech stocks. The S&amp;P 500 Ex-Information Technology Index is up less than 2% YTD, heavily underperforming the S&amp;P. This underperformance can be attributed to the rise of Generative AI, with companies such as Nvidia, Meta and Tesla contributing to a significant portion of the gains in tech. Best-Performing Stocks of Q1 2023 | Morningstar Macroeconomic Update The US economy is showing no signs of recession despite echoes from the Fed maintaining its hawkish stance. The labour market remains extremely tight with the unemployment rate at 3.6% as of Jun 2023. Following this week’s mixed job data, traders will be looki","listText":"Following a stellar start to 2023, the S&amp;P 500 index has now recorded close to a 15% gain year-to-date. However, most of the rally has been concentrated in Large Cap US Tech stocks. The S&amp;P 500 Ex-Information Technology Index is up less than 2% YTD, heavily underperforming the S&amp;P. This underperformance can be attributed to the rise of Generative AI, with companies such as Nvidia, Meta and Tesla contributing to a significant portion of the gains in tech. Best-Performing Stocks of Q1 2023 | Morningstar Macroeconomic Update The US economy is showing no signs of recession despite echoes from the Fed maintaining its hawkish stance. The labour market remains extremely tight with the unemployment rate at 3.6% as of Jun 2023. Following this week’s mixed job data, traders will be looki","text":"Following a stellar start to 2023, the S&P 500 index has now recorded close to a 15% gain year-to-date. However, most of the rally has been concentrated in Large Cap US Tech stocks. The S&P 500 Ex-Information Technology Index is up less than 2% YTD, heavily underperforming the S&P. This underperformance can be attributed to the rise of Generative AI, with companies such as Nvidia, Meta and Tesla contributing to a significant portion of the gains in tech. Best-Performing Stocks of Q1 2023 | Morningstar Macroeconomic Update The US economy is showing no signs of recession despite echoes from the Fed maintaining its hawkish stance. The labour market remains extremely tight with the unemployment rate at 3.6% as of Jun 2023. Following this week’s mixed job data, traders will be looki","images":[{"img":"https://community-static.tradeup.com/news/419b91f9fb0ebfcd980bbccfb4dfb777","width":"822","height":"391"},{"img":"https://community-static.tradeup.com/news/e3120e60c1a6905174936d050d4a3b88","width":"660","height":"477"},{"img":"https://community-static.tradeup.com/news/b4d0b65639b058b64a984d0bd1d67ca0","width":"828","height":"415"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196493603737608","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186910590034000,"gmtCreate":1686671744098,"gmtModify":1686671747943,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186910590034000","repostId":"9970552160","repostType":1,"repost":{"id":9970552160,"gmtCreate":1684749190550,"gmtModify":1686053338540,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"Light up your investing with Tiger, play and win prizes worth up to USD 999","htmlText":"🔥 Join our exclusive \"Light up Your Investing\" campaign with Tiger! 💼💰Participate in our game and win fantastic USD 999 prizes! 🎉🤑Unveil the allure of various regions as you progress through exciting game levels. 🌍But wait, there's more! Along your journey, uncover hidden rewards and unlock exclusive bonuses that will supercharge your investing game! 🎁💎Not only will you gain valuable knowledge and insights, but you'll also compete with fellow investors for the top spot on our leaderboard! 🏆🚀Tag your friends and embark on this epic investing adventure together! Let's light up the world of investing with Tiger! 🐯✨Don't miss out on this limited-time opportunity! Campaign period: 6th June to 27th June.*T&amp;Cs apply.👉<a href=\"https://tigr.link/lightupau\" target=\"_blank\"> Click here to start p</a>","listText":"🔥 Join our exclusive \"Light up Your Investing\" campaign with Tiger! 💼💰Participate in our game and win fantastic USD 999 prizes! 🎉🤑Unveil the allure of various regions as you progress through exciting game levels. 🌍But wait, there's more! Along your journey, uncover hidden rewards and unlock exclusive bonuses that will supercharge your investing game! 🎁💎Not only will you gain valuable knowledge and insights, but you'll also compete with fellow investors for the top spot on our leaderboard! 🏆🚀Tag your friends and embark on this epic investing adventure together! Let's light up the world of investing with Tiger! 🐯✨Don't miss out on this limited-time opportunity! Campaign period: 6th June to 27th June.*T&amp;Cs apply.👉<a href=\"https://tigr.link/lightupau\" target=\"_blank\"> Click here to start p</a>","text":"🔥 Join our exclusive \"Light up Your Investing\" campaign with Tiger! 💼💰Participate in our game and win fantastic USD 999 prizes! 🎉🤑Unveil the allure of various regions as you progress through exciting game levels. 🌍But wait, there's more! Along your journey, uncover hidden rewards and unlock exclusive bonuses that will supercharge your investing game! 🎁💎Not only will you gain valuable knowledge and insights, but you'll also compete with fellow investors for the top spot on our leaderboard! 🏆🚀Tag your friends and embark on this epic investing adventure together! Let's light up the world of investing with Tiger! 🐯✨Don't miss out on this limited-time opportunity! Campaign period: 6th June to 27th June.*T&Cs apply.👉 Click here to start p","images":[{"img":"https://community-static.tradeup.com/news/93315f0145d9ad782d2cab5f5dea10d7","width":"1200","height":"675"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9970552160","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":1,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183342836047952,"gmtCreate":1685782737468,"gmtModify":1685782741263,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183342836047952","repostId":"183318861013008","repostType":1,"repost":{"id":183318861013008,"gmtCreate":1685777195696,"gmtModify":1685778488930,"author":{"id":"4112162097902942","authorId":"4112162097902942","name":"DoTrading","avatar":"https://community-static.tradeup.com/news/b836687d88c2c5ee60f65e3d53461ef7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4112162097902942","authorIdStr":"4112162097902942"},"themes":[],"title":"SPX-Greedy...or Not...","htmlText":"CONTENT: Summary - Main events - Market scenario - SPX levels - Agenda. <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> rose 1.5%, taking its weekly gain to 1.8%. <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> continued its advance with 1.1% to hit a 52-week high. He gained 2% weekly, extending his winning streak to six weeks. (longest winning streak since January 2020). <a href=\"https://ttm.financial/S/.DJI\">$DJIA(.DJI)$</a> by 2.1%, with the biggest one-day point gain for the Dow Jones since Nov. 30, 2022 (about 701 points). Although big tech stocks have gone it alone in recent weeks, raising questions about the real breadth of the market, on Friday all 11 sectors of the S&amp;P 500 rose... Market valuation The reset in VVIX and skew this week has been absol","listText":"CONTENT: Summary - Main events - Market scenario - SPX levels - Agenda. <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> rose 1.5%, taking its weekly gain to 1.8%. <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> continued its advance with 1.1% to hit a 52-week high. He gained 2% weekly, extending his winning streak to six weeks. (longest winning streak since January 2020). <a href=\"https://ttm.financial/S/.DJI\">$DJIA(.DJI)$</a> by 2.1%, with the biggest one-day point gain for the Dow Jones since Nov. 30, 2022 (about 701 points). Although big tech stocks have gone it alone in recent weeks, raising questions about the real breadth of the market, on Friday all 11 sectors of the S&amp;P 500 rose... Market valuation The reset in VVIX and skew this week has been absol","text":"CONTENT: Summary - Main events - Market scenario - SPX levels - Agenda. $S&P 500(.SPX)$ rose 1.5%, taking its weekly gain to 1.8%. $NASDAQ(.IXIC)$ continued its advance with 1.1% to hit a 52-week high. He gained 2% weekly, extending his winning streak to six weeks. (longest winning streak since January 2020). $DJIA(.DJI)$ by 2.1%, with the biggest one-day point gain for the Dow Jones since Nov. 30, 2022 (about 701 points). Although big tech stocks have gone it alone in recent weeks, raising questions about the real breadth of the market, on Friday all 11 sectors of the S&P 500 rose... Market valuation The reset in VVIX and skew this week has been absol","images":[{"img":"https://community-static.tradeup.com/news/96177d81fd16df6c76a10c71a34ad39e","width":"613","height":"401"},{"img":"https://community-static.tradeup.com/news/634724ae91624bc074c808c6629bbc0c","width":"801","height":"516"},{"img":"https://community-static.tradeup.com/news/7c99c2fe88b48164f47acb826811b43c","width":"1167","height":"971"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183318861013008","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947482530,"gmtCreate":1683503517221,"gmtModify":1683503519944,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947482530","repostId":"2332241389","repostType":2,"repost":{"id":"2332241389","pubTimestamp":1683113400,"share":"https://ttm.financial/m/news/2332241389?lang=&edition=fundamental","pubTime":"2023-05-03 19:30","market":"us","language":"en","title":"Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2332241389","media":"GlobeNewswire","summary":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomi","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/99cgRTjjmIlIU2OVWMbZ5w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/53a1e9b470d0b8db47e46ddd9872cbf3\" title=\"HMI Logo_020216.jpg\" vspace=\"5\"/>\n<p><strong><em>-</em></strong> <strong><em>First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -</em></strong><br/></p>\n<p>BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene &amp; Cell Therapy (ASGCT) 26<sup>th </sup>Annual Meeting from May 16-20, 2023.</p>\n<p>“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”<br/><br/>Homology’s ASGCT 2023 presentations will include:<br/><br/></p>\n<p><strong>HMI-104: GTx-mAb Development Candidate for PNH</strong><br/>Preclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 386</li>\n</ul>\n<p><strong>AAVHSC Platform</strong><br/>Ocular Biodistribution of AAVHSCs Across Species and Routes of Administration<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 376</li>\n</ul>\n<p><strong>Immunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS II</strong><br/>Targeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches<br/></p>\n<ul type=\"disc\">\n<li>Thursday, May 18 at 12:00 p.m. PT</li>\n<li>Abstract # 989<br/></li>\n</ul>\n<p><strong>HMI-204: Gene Therapy Candidate for MLD</strong><br/>Gene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1312</li>\n</ul>\n<p><strong>AAVHSC Re-Dosing</strong><br/>Re-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1355</li>\n</ul>\n<p><strong>AAVHSC-Mediated, Homologous Recombination-Based Gene Editing</strong><br/>Method for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1497<br/></li>\n</ul>\n<p>The abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.</p>\n<p><strong>About Homology Medicines, Inc.</strong><br/>Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines <em>in vivo</em> through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.<br/></p>\n<p><strong>Forward-Looking Statements </strong><br/>This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.<br/></p>\n<p><strong>Company Contacts:</strong><br/>Cara Mayfield<br/>Vice President, Patient Advocacy<br/>and Corporate Communications<br/>cmayfield@homologymedicines.com<br/>781-691-3510<br/><br/><strong>Investor Contact:</strong><br/>Brad Smith <br/>Chief Financial and Business Officer <br/>bsmith@homologymedicines.com <br/>781-301-7277<br/><br/><br/><br/><br/><br/><br/><br/><br/><br/><br/></p>\n<br/>\n<img src=\"https://ml.globenewswire.com/media/ZTI0NzJlY2MtMGM1Yy00ZjY5LWI2OGEtZTE5MDE4YzdmZjZlLTExMDk1MTQ=/tiny/Homology-Medicines-Inc-.png\"/>\n<br/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHomology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-03 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE ...</p>\n\n<a href=\"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/PnhYAqM5zRCGitBIclIvxg--~B/aD05NTA7dz0zODgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/35ccf701601c31a2229a441cf35a80c2","relate_stocks":{"NGD":"New Gold","MDCO":"麦迪逊医药","BK4139":"生物科技","GENE":"基因技术ADR","BK4570":"地缘局势概念股","BK4017":"黄金","BK4121":"生命科学工具和服务","BK4535":"淡马锡持仓"},"source_url":"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2332241389","content_text":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting from May 16-20, 2023.\n“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”Homology’s ASGCT 2023 presentations will include:\nHMI-104: GTx-mAb Development Candidate for PNHPreclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 386\n\nAAVHSC PlatformOcular Biodistribution of AAVHSCs Across Species and Routes of Administration\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 376\n\nImmunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS IITargeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches\n\nThursday, May 18 at 12:00 p.m. PT\nAbstract # 989\n\nHMI-204: Gene Therapy Candidate for MLDGene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1312\n\nAAVHSC Re-DosingRe-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1355\n\nAAVHSC-Mediated, Homologous Recombination-Based Gene EditingMethod for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1497\n\nThe abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.\nAbout Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.\nForward-Looking Statements This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.\nCompany Contacts:Cara MayfieldVice President, Patient Advocacyand Corporate Communicationscmayfield@homologymedicines.com781-691-3510Investor Contact:Brad Smith Chief Financial and Business Officer bsmith@homologymedicines.com 781-301-7277","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947482295,"gmtCreate":1683503510618,"gmtModify":1683503514291,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947482295","repostId":"2332241389","repostType":2,"repost":{"id":"2332241389","pubTimestamp":1683113400,"share":"https://ttm.financial/m/news/2332241389?lang=&edition=fundamental","pubTime":"2023-05-03 19:30","market":"us","language":"en","title":"Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2332241389","media":"GlobeNewswire","summary":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomi","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/99cgRTjjmIlIU2OVWMbZ5w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/53a1e9b470d0b8db47e46ddd9872cbf3\" title=\"HMI Logo_020216.jpg\" vspace=\"5\"/>\n<p><strong><em>-</em></strong> <strong><em>First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -</em></strong><br/></p>\n<p>BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene &amp; Cell Therapy (ASGCT) 26<sup>th </sup>Annual Meeting from May 16-20, 2023.</p>\n<p>“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”<br/><br/>Homology’s ASGCT 2023 presentations will include:<br/><br/></p>\n<p><strong>HMI-104: GTx-mAb Development Candidate for PNH</strong><br/>Preclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 386</li>\n</ul>\n<p><strong>AAVHSC Platform</strong><br/>Ocular Biodistribution of AAVHSCs Across Species and Routes of Administration<br/></p>\n<ul type=\"disc\">\n<li>Wednesday, May 17 at 12:00 p.m. PT</li>\n<li>Abstract # 376</li>\n</ul>\n<p><strong>Immunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS II</strong><br/>Targeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches<br/></p>\n<ul type=\"disc\">\n<li>Thursday, May 18 at 12:00 p.m. PT</li>\n<li>Abstract # 989<br/></li>\n</ul>\n<p><strong>HMI-204: Gene Therapy Candidate for MLD</strong><br/>Gene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1312</li>\n</ul>\n<p><strong>AAVHSC Re-Dosing</strong><br/>Re-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1355</li>\n</ul>\n<p><strong>AAVHSC-Mediated, Homologous Recombination-Based Gene Editing</strong><br/>Method for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors<br/></p>\n<ul type=\"disc\">\n<li>Friday, May 19 at 12:00 p.m. PT</li>\n<li>Abstract # 1497<br/></li>\n</ul>\n<p>The abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.</p>\n<p><strong>About Homology Medicines, Inc.</strong><br/>Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines <em>in vivo</em> through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.<br/></p>\n<p><strong>Forward-Looking Statements </strong><br/>This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.<br/></p>\n<p><strong>Company Contacts:</strong><br/>Cara Mayfield<br/>Vice President, Patient Advocacy<br/>and Corporate Communications<br/>cmayfield@homologymedicines.com<br/>781-691-3510<br/><br/><strong>Investor Contact:</strong><br/>Brad Smith <br/>Chief Financial and Business Officer <br/>bsmith@homologymedicines.com <br/>781-301-7277<br/><br/><br/><br/><br/><br/><br/><br/><br/><br/><br/></p>\n<br/>\n<img src=\"https://ml.globenewswire.com/media/ZTI0NzJlY2MtMGM1Yy00ZjY5LWI2OGEtZTE5MDE4YzdmZjZlLTExMDk1MTQ=/tiny/Homology-Medicines-Inc-.png\"/>\n<br/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHomology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-03 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE ...</p>\n\n<a href=\"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/PnhYAqM5zRCGitBIclIvxg--~B/aD05NTA7dz0zODgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/35ccf701601c31a2229a441cf35a80c2","relate_stocks":{"NGD":"New Gold","MDCO":"麦迪逊医药","BK4139":"生物科技","GENE":"基因技术ADR","BK4570":"地缘局势概念股","BK4017":"黄金","BK4121":"生命科学工具和服务","BK4535":"淡马锡持仓"},"source_url":"https://finance.yahoo.com/news/homology-medicines-announces-upcoming-presentations-113000626.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2332241389","content_text":"- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -\nBEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of functional C5 monoclonal antibody (C5mAb) levels in multiple preclinical models. Homology will also present for the first time non-clinical data that show the potential for AAVHSC re-dosing across different clades of viruses. These presentations, alongside additional data supporting the Company’s gene editing and gene therapy programs, will be featured at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting from May 16-20, 2023.\n“These new data to be presented during ASGCT with our GTx-mAb development candidate, HMI-104, support its development as a one-time treatment for the rare, acquired disorder PNH, with potential for the platform to address other complement-mediated disorders,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “We also look forward to unveiling data that demonstrate the ability to re-dose AAVHSCs across different virus clades, which is of particular importance as the field continues to focus on AAV re-dosing strategies. Additional presentations will highlight work across our AAVHSC platform, including methods to further characterize genomic targets with the highest likelihood of homologous recombination-based gene editing, as we work toward our goal of delivering best-in-class gene editing therapies.”Homology’s ASGCT 2023 presentations will include:\nHMI-104: GTx-mAb Development Candidate for PNHPreclinical Studies with HMI-104, an AAVHSC Vectorized C5 Monoclonal Antibody, for the Treatment of PNH\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 386\n\nAAVHSC PlatformOcular Biodistribution of AAVHSCs Across Species and Routes of Administration\n\nWednesday, May 17 at 12:00 p.m. PT\nAbstract # 376\n\nImmunosuppression Regimen Used in Ongoing Clinical Trials for PKU and MPS IITargeted Approach to Immunosuppression with AAV Gene Therapy: Nonclinical Support of Clinical Approaches\n\nThursday, May 18 at 12:00 p.m. PT\nAbstract # 989\n\nHMI-204: Gene Therapy Candidate for MLDGene Therapy Candidate for Metachromatic Leukodystrophy (MLD): Optimization of HMI-202 Leading to HMI-204 Nomination\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1312\n\nAAVHSC Re-DosingRe-Dosing of Liver-Targeted AAV within and Across Clades in Mice: Effects of Neutralizing Antibodies and Vector-Specific Factors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1355\n\nAAVHSC-Mediated, Homologous Recombination-Based Gene EditingMethod for Identification and Characterization of Sites of Homology Directed Strand Cross-Over Using rAAV Integration Vectors\n\nFriday, May 19 at 12:00 p.m. PT\nAbstract # 1497\n\nThe abstracts are available on the ASGCT website and on the Publications and Presentations page on Homology’s website.\nAbout Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.\nForward-Looking Statements This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including HMI 104 for the treatment of PNH and other diseases; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.\nCompany Contacts:Cara MayfieldVice President, Patient Advocacyand Corporate Communicationscmayfield@homologymedicines.com781-691-3510Investor Contact:Brad Smith Chief Financial and Business Officer bsmith@homologymedicines.com 781-301-7277","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947870321,"gmtCreate":1682989638663,"gmtModify":1682989642276,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947870321","repostId":"9947813329","repostType":1,"repost":{"id":9947813329,"gmtCreate":1682870524062,"gmtModify":1682901733820,"author":{"id":"4113904591642392","authorId":"4113904591642392","name":"LMSunshine","avatar":"https://community-static.tradeup.com/news/0ad636f2490d8428fcee9da6d669e46c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4113904591642392","authorIdStr":"4113904591642392"},"themes":[],"title":"🐂🐂🐂 About Apple🍎 Earnings & Share Price🥳","htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;ended at an 8-month peak of $169.68 on 28/4 (Fri), the highest level since 26/8/22🐂🐂🐂 At its current valuation, 🍎 has a market cap of $2.68 trillion, making it the most valuable company trading on the 🇺🇸 stock exchange. Shares are up 30.6% so far in 2023, almost quadrupling the 7.7% rise in the S&amp;P 500 index, was&nbsp;outperforming the broader market by a wide margin over the same timeframe🥳🥳🥳 ⭐️&nbsp;I expect 🍎 to follow 🐂-ish earnings reports MSFT, GOOGL, META,&nbsp;&amp; AMZN last week&nbsp;<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/META\">$Meta Platforms</a>","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;ended at an 8-month peak of $169.68 on 28/4 (Fri), the highest level since 26/8/22🐂🐂🐂 At its current valuation, 🍎 has a market cap of $2.68 trillion, making it the most valuable company trading on the 🇺🇸 stock exchange. Shares are up 30.6% so far in 2023, almost quadrupling the 7.7% rise in the S&amp;P 500 index, was&nbsp;outperforming the broader market by a wide margin over the same timeframe🥳🥳🥳 ⭐️&nbsp;I expect 🍎 to follow 🐂-ish earnings reports MSFT, GOOGL, META,&nbsp;&amp; AMZN last week&nbsp;<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$&nbsp;</a>Bullish<a href=\"https://ttm.financial/S/META\">$Meta Platforms</a>","text":"$Apple(AAPL)$ ended at an 8-month peak of $169.68 on 28/4 (Fri), the highest level since 26/8/22🐂🐂🐂 At its current valuation, 🍎 has a market cap of $2.68 trillion, making it the most valuable company trading on the 🇺🇸 stock exchange. Shares are up 30.6% so far in 2023, almost quadrupling the 7.7% rise in the S&P 500 index, was outperforming the broader market by a wide margin over the same timeframe🥳🥳🥳 ⭐️ I expect 🍎 to follow 🐂-ish earnings reports MSFT, GOOGL, META, & AMZN last week $Alphabet(GOOGL)$ Bullish$Amazon.com(AMZN)$ Bullish$Meta Platforms","images":[{"img":"https://community-static.tradeup.com/news/780d5c3ae21556b4cda00fddb1bb9b1c","width":"873","height":"808"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947813329","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947870950,"gmtCreate":1682989623170,"gmtModify":1682989627004,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947870950","repostId":"9947884997","repostType":1,"repost":{"id":9947884997,"gmtCreate":1682922581919,"gmtModify":1682923112776,"author":{"id":"9000000000000439","authorId":"9000000000000439","name":"TigerObserver","avatar":"https://static.tigerbbs.com/2f3a05d038882153678ee817929431fc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000439","authorIdStr":"9000000000000439"},"themes":[],"title":"Weekly: Fed Decisions; Apple Earnings; FRC to highlight the Week","htmlText":"US MARKET RECAPLast week, all the major index close in green with a deep V-shaped pattern. The blue-chip index, Dow added 0.86%, while the S&amp;P 500 rose 0.87%. The Nasdaq advanced 1.28% as Big Tech earnings took center stage.For April, the Dow gained 2.48% to notch its best monthly stretch since January, while the benchmark index gained 1.46%. The tech-heavy index posted marginal gains.Earnings reports from major tech companies dominated much of last week’s market debate, fueling the narrative that earnings are faring better-than-feared, despite many widespread macroeconomic concerns.So far, a little over half of S&amp;P 500 companies have reported earnings, with more than 79% and about 72% surpassing earnings and sales expectations, respectively. First-quarter earnings are currently on","listText":"US MARKET RECAPLast week, all the major index close in green with a deep V-shaped pattern. The blue-chip index, Dow added 0.86%, while the S&amp;P 500 rose 0.87%. The Nasdaq advanced 1.28% as Big Tech earnings took center stage.For April, the Dow gained 2.48% to notch its best monthly stretch since January, while the benchmark index gained 1.46%. The tech-heavy index posted marginal gains.Earnings reports from major tech companies dominated much of last week’s market debate, fueling the narrative that earnings are faring better-than-feared, despite many widespread macroeconomic concerns.So far, a little over half of S&amp;P 500 companies have reported earnings, with more than 79% and about 72% surpassing earnings and sales expectations, respectively. First-quarter earnings are currently on","text":"US MARKET RECAPLast week, all the major index close in green with a deep V-shaped pattern. The blue-chip index, Dow added 0.86%, while the S&P 500 rose 0.87%. The Nasdaq advanced 1.28% as Big Tech earnings took center stage.For April, the Dow gained 2.48% to notch its best monthly stretch since January, while the benchmark index gained 1.46%. The tech-heavy index posted marginal gains.Earnings reports from major tech companies dominated much of last week’s market debate, fueling the narrative that earnings are faring better-than-feared, despite many widespread macroeconomic concerns.So far, a little over half of S&P 500 companies have reported earnings, with more than 79% and about 72% surpassing earnings and sales expectations, respectively. First-quarter earnings are currently on","images":[{"img":"https://community-static.tradeup.com/news/bf50b77b83d4fe0ebd4152acd2c424e5","width":"974","height":"1110"},{"img":"https://community-static.tradeup.com/news/d6a9ce360893b3b14136d9dc3804bf07","width":"1290","height":"498"},{"img":"https://community-static.tradeup.com/news/334f7f736dd80a6544ee9931d422b2ff","width":"1080","height":"1920"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947884997","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947870042,"gmtCreate":1682989558987,"gmtModify":1682989562428,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947870042","repostId":"9947897984","repostType":1,"repost":{"id":9947897984,"gmtCreate":1682822470348,"gmtModify":1682822503705,"author":{"id":"10000000000010945","authorId":"10000000000010945","name":"Meme_Tiger","avatar":"https://community-static.tradeup.com/news/eb1a09788252e1f02cd561cbf0b1ac99","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"10000000000010945","authorIdStr":"10000000000010945"},"themes":[],"title":"Top Meme Stocks| China Meme Mania is Back! Will FRC Go Bankrupt?","htmlText":"Hi, tigers! I gonna track meme stocks’ movement every week and inform you of the hottest meme stocks in one week and why did they gain most attention. If you were also interested in meme stocks, follow me and learn the news about short squeeze every Friday! 💖💖I gonna present you the top gainers/losers in meme stocks this week!Market manipulation behind China meme stocks mania?Nate Anderson, the Founder of short seller activist firm Hindenburg Research, believes that market manipulation is the culprit behind the outsized gains&nbsp;of <a href=\"https://ttm.financial/S/TOP\">$Zhong Yang Financial Group Ltd(TOP)$</a>, <a href=\"https://ttm.financial/S/MEGL\">$Magic Empire Global Ltd(MEGL)$</a> and <a href=\"https://ttm.financial/S/HKD\">$AMTD Digital Inc.(HKD)$</a> .Since last November, Anderson ha","listText":"Hi, tigers! I gonna track meme stocks’ movement every week and inform you of the hottest meme stocks in one week and why did they gain most attention. If you were also interested in meme stocks, follow me and learn the news about short squeeze every Friday! 💖💖I gonna present you the top gainers/losers in meme stocks this week!Market manipulation behind China meme stocks mania?Nate Anderson, the Founder of short seller activist firm Hindenburg Research, believes that market manipulation is the culprit behind the outsized gains&nbsp;of <a href=\"https://ttm.financial/S/TOP\">$Zhong Yang Financial Group Ltd(TOP)$</a>, <a href=\"https://ttm.financial/S/MEGL\">$Magic Empire Global Ltd(MEGL)$</a> and <a href=\"https://ttm.financial/S/HKD\">$AMTD Digital Inc.(HKD)$</a> .Since last November, Anderson ha","text":"Hi, tigers! I gonna track meme stocks’ movement every week and inform you of the hottest meme stocks in one week and why did they gain most attention. If you were also interested in meme stocks, follow me and learn the news about short squeeze every Friday! 💖💖I gonna present you the top gainers/losers in meme stocks this week!Market manipulation behind China meme stocks mania?Nate Anderson, the Founder of short seller activist firm Hindenburg Research, believes that market manipulation is the culprit behind the outsized gains of $Zhong Yang Financial Group Ltd(TOP)$, $Magic Empire Global Ltd(MEGL)$ and $AMTD Digital Inc.(HKD)$ .Since last November, Anderson ha","images":[{"img":"https://community-static.tradeup.com/news/ed8bf5f917994ecf93bc0a19ff6630a8","width":"1587","height":"2245"},{"img":"https://community-static.tradeup.com/news/c13649877e01553d6c61d48db7e5a002","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/53438bceca949c0b15f9236457167634","width":"560","height":"240"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947897984","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":6,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947908126,"gmtCreate":1682417828766,"gmtModify":1682417832063,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/LUMN\">$Lumen Technologies(LUMN)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/LUMN\">$Lumen Technologies(LUMN)$ &nbsp;</a>","text":"$Lumen Technologies(LUMN)$","images":[{"img":"https://community-static.tradeup.com/news/457f0f1e3fd88eb3fd110aa06d6af1ff","width":"720","height":"1234"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947908126","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9944406031,"gmtCreate":1681982854323,"gmtModify":1681982858247,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ &nbsp;</a>","text":"$Tesla Motors(TSLA)$","images":[{"img":"https://community-static.tradeup.com/news/06caafdcb35963c0104fa529a0c34fc3","width":"720","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9944406031","isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9945769302,"gmtCreate":1681599157107,"gmtModify":1681599161012,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945769302","repostId":"9945610651","repostType":1,"repost":{"id":9945610651,"gmtCreate":1681446196173,"gmtModify":1681446338358,"author":{"id":"3501196737273098","authorId":"3501196737273098","name":"Tiger_comments","avatar":"https://community-static.tradeup.com/news/227887b200e9925968650d5db4a8bfb3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3501196737273098","authorIdStr":"3501196737273098"},"themes":[],"title":"[TOPIC] Chip vs. New Energy: which one to choose?","htmlText":"The market’s favorite has been changing over years as ChatGPT concept is the most-heated topic. While back in 2021, new energy vehicle was the beloved one.New King - SemiconductorSince the end of last year, ChatGPT concept has become very popular. The AI sector has also risen accordingly. The ChatGPT concept in the US stock market has risen by 30%.Since this year is a technology bull market, the chip behind artificial intelligence will naturally not be absent. On April 6, the ChatGPT official announced the suspension of the Plus version (a $20/month subscription version).The reason is due to the tightness of the computing power and the increased demand for high-end chips. With the development of the AI, the demand for high-performance GPUs will also increase.In addition, the market general","listText":"The market’s favorite has been changing over years as ChatGPT concept is the most-heated topic. While back in 2021, new energy vehicle was the beloved one.New King - SemiconductorSince the end of last year, ChatGPT concept has become very popular. The AI sector has also risen accordingly. The ChatGPT concept in the US stock market has risen by 30%.Since this year is a technology bull market, the chip behind artificial intelligence will naturally not be absent. On April 6, the ChatGPT official announced the suspension of the Plus version (a $20/month subscription version).The reason is due to the tightness of the computing power and the increased demand for high-end chips. With the development of the AI, the demand for high-performance GPUs will also increase.In addition, the market general","text":"The market’s favorite has been changing over years as ChatGPT concept is the most-heated topic. While back in 2021, new energy vehicle was the beloved one.New King - SemiconductorSince the end of last year, ChatGPT concept has become very popular. The AI sector has also risen accordingly. The ChatGPT concept in the US stock market has risen by 30%.Since this year is a technology bull market, the chip behind artificial intelligence will naturally not be absent. On April 6, the ChatGPT official announced the suspension of the Plus version (a $20/month subscription version).The reason is due to the tightness of the computing power and the increased demand for high-end chips. With the development of the AI, the demand for high-performance GPUs will also increase.In addition, the market general","images":[{"img":"https://community-static.tradeup.com/news/53eefa35ac2faa2727117903497aec91","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/d5e6e9ebaea7764a2f57b3666f7b054e","width":"837","height":"371"},{"img":"https://community-static.tradeup.com/news/5ffbc693d8e02a960f8113d15348ab7e","width":"1245","height":"320"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945610651","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9946706528,"gmtCreate":1681046652465,"gmtModify":1681046655830,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946706528","repostId":"9946706174","repostType":1,"isVote":1,"tweetType":1,"viewCount":61,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9946706649,"gmtCreate":1681046628581,"gmtModify":1681046635231,"author":{"id":"4140236792428712","authorId":"4140236792428712","name":"tear_reaper","avatar":"https://community-static.tradeup.com/news/0d0a17ef350ac182b327f7a6e2d0669b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4140236792428712","authorIdStr":"4140236792428712"},"themes":[],"htmlText":"Love this opportunity they have during easter","listText":"Love this opportunity they have during easter","text":"Love this opportunity they have during easter","images":[{"img":"https://community-static.tradeup.com/news/1d94e85eaebdbfcb6ef32b9b6aed7eb3","width":"580","height":"2319"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9946706649","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}